Established breast cancer stem cell markers do not correlate with in vivo tumorigenicity of tumor-initiating cells
Open Access
- 5 October 2012
- journal article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 41 (6) , 1932-1942
Abstract
The tumor-initiating capacity of primary human breast cancer cells is maintained in vitro by culturing these cells as spheres/aggregates. Inoculation of small cell numbers derived from these non-adherent cultures leads to rapid xenograft tumor formation in mice. Accordingly, injection of more differentiated monolayer cells derived from spheres results in significantly decelerated tumor growth. For our study, two breast cancer cell lines were generated from primary tumors and cultured as mammospheres or as their adherent counterparts. We examined the in vivo tumorigenicity of these cells by injecting serial dilutions into immunodeficient mice. Inoculation of 106 cells per mouse led to rapid tumor formation, irrespective of cell line or culture conditions. However, after injection of only 103 cells, solely sphere cells were highly tumorigenic. In vitro, we investigated differentiation markers, established breast CSC markers and conducted mRNA profiling. Cytokeratin 5 and 18 were increased in both monolayer cell types, indicating a more differentiated phenotype. All cell lines were CD24(-)/CD44(+) and did not express CD133, CD326 or E-cadherin. ALDH1 activity was not detectable in any cell line. A verapamil‑sensitive Hoechst side population was present in sphere cells, but there was no correlation with tumorigenicity in vivo. mRNA profiling did not reveal upregulation of relevant transcription factors. In vitro cell cycle kinetics and in vivo tumor doubling times displayed no difference between sphere and monolayer cultures. Our data indicate that intrinsic genetic and functional markers investigated are not indicative of the in vivo tumori-genicity of putative breast tumor-initiating cells.Keywords
This publication has 40 references indexed in Scilit:
- Immunoselection of Breast and Ovarian Cancer Cells with Trastuzumab and Natural Killer Cells: Selective Escape of CD44high/CD24low/HER2low Breast Cancer Stem CellsCancer Research, 2009
- Cancer stem cells in breast cancer and metastasisBreast Cancer Research and Treatment, 2009
- Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating featuresProceedings of the National Academy of Sciences, 2009
- The Hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24-/low subpopulation and the side population of breast cancer cells.2009
- Tumor initiating cancer stem cells from human breast cancer cell linesInternational Journal of Oncology, 2009
- Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traitsNature Reviews Cancer, 2009
- Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular SignatureCancer Research, 2009
- CAMK1D amplification implicated in epithelial–mesenchymal transition in basal‐like breast cancerMolecular Oncology, 2008
- Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cellsBreast Cancer Research, 2008
- Recent advances in cancer stem cellsCurrent Opinion in Genetics & Development, 2008